Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives

術前はICI単剤よりは何かしら併用が良い。 Ipi併用のNEOSTARのpCR率の高さを考慮すると、Chemoに拘らずに最適な組み合わせを見つけていきたいもの。 当初から術前のctDNA値とOSの関連に言及していたNADIM試験は優秀。 https://t.co/MdlImPeXSI https://t.co/sjilHy0h5Z

RT @markma666666: Happy to co-author this back-to-back paper: "Emerging precision neoadjuvant systemic therapy for patients with resectabl…

👏🏻👏🏻👏🏻

Happy to co-author this back-to-back paper: "Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives." Excellent figures and tables with comprehensive contents. https://t.co/